Generic Name:
glucagon
Project Status:
Complete
Therapeutic Area:
Severe hypoglycemic reactions
Manufacturer:
Eli Lilly Canada Inc.
Call for patient/clinician input open:
Brand Name:
Baqsimi
Project Line:
Reimbursement Review
Project Number:
SR0626-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Details
Manufacturer Requested Reimbursement Criteria1:
For the treatment of severe hypoglycemic reactions which may occur in the management of insulin treated patients with diabetes mellitus, when impaired consciousness precludes oral carbohydrates.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Severe hypoglycemic reactions
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.